Doximity Dirección

Dirección controles de criterios 3/4

El CEO de Doximity es Jeff Tangney , nombrado en Apr 2010, tiene una permanencia de 14.58 años. compensación anual total es $298.87K, compuesta por 98.7% salario y 1.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 27.21% de las acciones de la empresa, por valor de R$14.22B. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 9.2 años, respectivamente.

Información clave

Jeff Tangney

Chief Executive Officer (CEO)

US$298.9k

Compensación total

Porcentaje del salario del CEO	98.7%
Permanencia del CEO	14.6yrs
Participación del CEO	27.2%
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	9.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jeff Tangney en comparación con los beneficios de Doximity?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$174m
Jun 30 2024	n/a	n/a	US$161m
Mar 31 2024	US$299k	US$295k	US$148m
Dec 31 2023	n/a	n/a	US$138m
Sep 30 2023	n/a	n/a	US$123m
Jun 30 2023	n/a	n/a	US$119m
Mar 31 2023	US$244k	US$240k	US$113m
Dec 31 2022	n/a	n/a	US$119m
Sep 30 2022	n/a	n/a	US$141m
Jun 30 2022	n/a	n/a	US$148m
Mar 31 2022	US$243k	US$240k	US$133m
Dec 31 2021	n/a	n/a	US$107m
Sep 30 2021	n/a	n/a	US$57m
Jun 30 2021	n/a	n/a	US$30m
Mar 31 2021	US$21m	US$240k	US$22m

Compensación vs. Mercado: La compensación total de Jeff($USD298.87K) está por debajo de la media de empresas de tamaño similar en el mercado BR ($USD2.41M).

Compensación vs. Ingresos: La compensación de Jeff ha aumentado más de un 20% en el último año.

CEO

Jeff Tangney (51 yo)

14.6yrs

Permanencia

US$298,869

Compensación

Mr. Jeffrey A. Tangney, also known as Jeff, Co-Founded Doximity, Inc. in 2010 and has been its Chief Executive Officer and Director since April 2010 and serves as its Chairperson. Mr. Tangney also serves a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeffrey Tangney	Co-Founder	14.6yrs	US$298.87k	27.21% R$ 14.2b
Nate Gross	Co-Founder & Chief Strategy Officer	no data	US$305.47k	0.26% R$ 135.1m
Anna Bryson	Chief Financial Officer	3.8yrs	US$3.87m	0.13% R$ 65.6m
Jennifer Chaloemtiarana	General Counsel & Corporate Secretary	4.3yrs	US$603.94k	0.0032% R$ 1.7m
Craig Overpeck	Senior Vice President of Commercial Operations	1.5yrs	US$5.21m	0.011% R$ 6.0m
Shari Buck	Co-founder and SVP People & Ops	no data	sin datos	sin datos
Jey Balachandran	Chief Technology Officer	no data	sin datos	sin datos
Perry Gold	Head of Investor Relations	no data	sin datos	sin datos
Jim Rivas	Head of Corporate Communications	no data	sin datos	sin datos
Bruno Miranda	Senior Vice President of Engineering	no data	sin datos	sin datos
Joel Davis	Senior Vice President of Product	no data	sin datos	sin datos
Ben Greenberg	Senior VP & GM Commercial Products	1.5yrs	sin datos	sin datos

3.8yrs

Permanencia media

45.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de D2OC34 se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeffrey Tangney	Co-Founder	14.6yrs	US$298.87k	27.21% R$ 14.2b
Barry Chaiken	Member of Medical Advisory Board	no data	sin datos	sin datos
Timothy Cabral	Independent Director	4.2yrs	US$239.94k	0.0025% R$ 1.3m
Kevin Spain	Independent Director	13.7yrs	US$241.94k	0.16% R$ 86.1m
Lawrence Chin	Member of Medical Advisory Board	no data	sin datos	sin datos
Elise Brett	Member of Medical Advisory Board	no data	sin datos	sin datos
Bradley Cohn	Member of Medical Advisory Board	no data	sin datos	sin datos
Alexander Ding	Member of Medical Advisory Board	no data	sin datos	sin datos
Sharon Drost	Member of Medical Advisory Board	no data	sin datos	sin datos
Todd Ferris	Member of Medical Advisory Board	no data	sin datos	sin datos
Harvey Fishman	Member of Medical Advisory Board	no data	sin datos	sin datos
Kira Wampler	Independent Director	4.7yrs	US$233.94k	0.0055% R$ 2.9m

9.2yrs

Permanencia media

51.5yo

Promedio de edad

Junta con experiencia: La junta directiva de D2OC34 se considera experimentada (9.2 años de antigüedad promedio).

Doximity Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc., Annual General Meeting, Jul 26, 2023

Doximity, Inc. Announces Executive Appointment

Doximity, Inc. Appoints Phoebe Yang to Its Board of Directors

Doximity, Inc., Annual General Meeting, Jul 27, 2022

Recent updates

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Third Quarter Ending December 31, 2024 and Updating Earnings Guidance for Its Fiscal Year Ending March 31, 2025

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Doximity, Inc

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Doximity, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Doximity, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending December 31, 2023 and Fiscal Year Ending March 31, 2024

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $70 million worth of its shares.

Doximity Launches Docdefender, Expanding Services to Safeguard Physician Privacy

Doximity Launches Docdefender, Expanding Services to Safeguard Physician Privacy

Doximity, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Doximity, Inc. Provides Earnings Guidance for the Second Quarter Ending September 30, 2023 and Fiscal Year Ending March 31, 2024

Doximity, Inc. to Report Q1, 2024 Results on Aug 08, 2023

Doximity, Inc., Annual General Meeting, Jul 26, 2023

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $200 million worth of its shares.

Doximity, Inc. Announces Executive Appointment

Doximity, Inc. Provides Financial Guidance for the Fourth Quarter and Full Year Ending March 31, 2023 and for the Full Year Ending March 31, 2024

Doximity, Inc. Provides Financial Guidance for the Fourth Quarter and Full Year Ending March 31, 2023 and for the Full Year Ending March 31, 2024

Doximity, Inc. to Report Q3, 2023 Results on Feb 09, 2023

Doximity, Inc. Provides Earnings Guidance for the Third Quarter Ending December 31, 2022 and Reiterating Earnings Guidance for the Fiscal Year Ending March 31, 2023

Doximity, Inc. to Report Q2, 2023 Results on Nov 10, 2022

Doximity, Inc. Appoints Phoebe Yang to Its Board of Directors

Doximity, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Doximity, Inc., Annual General Meeting, Jul 27, 2022

Doximity, Inc. Provides Revenue Guidance for the Fiscal First Quarter Ending June 30, 2022 and for the Fiscal Year Ending March 31, 2023

Doximity, Inc. Provides Revenue Guidance for the First Quarter of 2023

Doximity, Inc. Provides Earnings Guidance for the Fiscal Fourth Quarter Ending March 31, 2022 and Fiscal Year Ending March 31, 2022

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad